Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ketamine: translating mechanistic discoveries into the next generation of glutamate modulators for mood disorders.

Literature DB >> 28070122

Ketamine: translating mechanistic discoveries into the next generation of glutamate modulators for mood disorders.

C A Zarate¹, R Machado-Vieira¹.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2017 PMID： 28070122 PMCID： PMC5641407 DOI： 10.1038/mp.2016.249

Source DB: PubMed Journal: Mol Psychiatry ISSN： 1359-4184 Impact factor: 15.992

× No keyword cloud information.

34 in total

1. Neural correlates of change in major depressive disorder anhedonia following open-label ketamine.

Authors: Níall Lally; Allison C Nugent; David A Luckenbaugh; Mark J Niciu; Jonathan P Roiser; Carlos A Zarate
Journal: J Psychopharmacol Date: 2015-02-17 Impact factor: 4.153

2. Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice.

Authors: E Beurel; L Song; R S Jope
Journal: Mol Psychiatry Date: 2011-04-19 Impact factor: 15.992

Review 3. Synaptic mechanisms underlying rapid antidepressant action of ketamine.

Authors: Ege T Kavalali; Lisa M Monteggia
Journal: Am J Psychiatry Date: 2012-11 Impact factor: 18.112

4. Acute suppression of spontaneous neurotransmission drives synaptic potentiation.

Authors: Elena Nosyreva; Kristen Szabla; Anita E Autry; Alexey G Ryazanov; Lisa M Monteggia; Ege T Kavalali
Journal: J Neurosci Date: 2013-04-17 Impact factor: 6.167

Review 5. Ketamine and the next generation of antidepressants with a rapid onset of action.

Authors: Rodrigo Machado-Vieira; Giacomo Salvadore; Nancy Diazgranados; Carlos A Zarate
Journal: Pharmacol Ther Date: 2009-05-03 Impact factor: 12.310

Review 6. Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks.

Authors: Frank S Menniti; Craig W Lindsley; P Jeffrey Conn; Jayvardhan Pandit; Panayiotis Zagouras; Robert A Volkmann
Journal: Curr Top Med Chem Date: 2013 Impact factor: 3.295

7. An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder.

Authors: Leorey N Saligan; David A Luckenbaugh; Elizabeth E Slonena; Rodrigo Machado-Vieira; Carlos A Zarate
Journal: J Affect Disord Date: 2016-01-19 Impact factor: 4.839

8. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

Authors: Sungho Maeng; Carlos A Zarate; Jing Du; Robert J Schloesser; Joseph McCammon; Guang Chen; Husseini K Manji
Journal: Biol Psychiatry Date: 2007-07-23 Impact factor: 13.382

9. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects.

Authors: Jeffrey Burgdorf; Xiao-lei Zhang; Katherine L Nicholson; Robert L Balster; J David Leander; Patric K Stanton; Amanda L Gross; Roger A Kroes; Joseph R Moskal
Journal: Neuropsychopharmacology Date: 2012-12-05 Impact factor: 7.853

10. Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors.

Authors: Ruin Moaddel; Galia Abdrakhmanova; Joanna Kozak; Krzysztof Jozwiak; Lawrence Toll; Lucita Jimenez; Avraham Rosenberg; Thao Tran; Yingxian Xiao; Carlos A Zarate; Irving W Wainer
Journal: Eur J Pharmacol Date: 2012-11-23 Impact factor: 4.432

12 in total

1. Ketamine and ketamine metabolites as novel estrogen receptor ligands: Induction of cytochrome P450 and AMPA glutamate receptor gene expression.

Authors: Ming-Fen Ho; Cristina Correia; James N Ingle; Rima Kaddurah-Daouk; Liewei Wang; Scott H Kaufmann; Richard M Weinshilboum
Journal: Biochem Pharmacol Date: 2018-04-03 Impact factor: 5.858

2. Acetyl-l-carnitine deficiency in patients with major depressive disorder.

Authors: Carla Nasca; Benedetta Bigio; Francis S Lee; Sarah P Young; Marin M Kautz; Ashly Albright; James Beasley; David S Millington; Aleksander A Mathé; James H Kocsis; James W Murrough; Bruce S McEwen; Natalie Rasgon
Journal: Proc Natl Acad Sci U S A Date: 2018-07-30 Impact factor: 11.205

Review 10. The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders.

Authors: M Kokkinou; A H Ashok; O D Howes
Journal: Mol Psychiatry Date: 2017-10-03 Impact factor: 15.992

Ketamine: translating mechanistic discoveries into the next generation of glutamate modulators for mood disorders.

1. Neural correlates of change in major depressive disorder anhedonia following open-label ketamine.

2. Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice.

Review 3. Synaptic mechanisms underlying rapid antidepressant action of ketamine.

4. Acute suppression of spontaneous neurotransmission drives synaptic potentiation.

Review 5. Ketamine and the next generation of antidepressants with a rapid onset of action.

Review 6. Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks.

7. An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder.

8. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

9. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects.

10. Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors.

1. Ketamine and ketamine metabolites as novel estrogen receptor ligands: Induction of cytochrome P450 and AMPA glutamate receptor gene expression.

2. Acetyl-l-carnitine deficiency in patients with major depressive disorder.

3. Not So Fast: Recent Successes and Failures in Treating Depression.

4. The development of glutamate-based antidepressants is taking longer than expected.

5. Right Frontal Theta: Is It a Response Biomarker for Ketamine's Therapeutic Action in Anxiety Disorders?

6. The Effect of Acutely Administered Propofol on Forced Swim Test Outcomes in Mice.

Review 7. Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.

Review 8. iPlasticity: Induced juvenile-like plasticity in the adult brain as a mechanism of antidepressants.

9. The Effect of Propofol on a Forced Swim Test in Mice at 24 Hours.

Review 10. The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders.